KRAS and non-small cell lung carcinoma: STK11LOF occurs in approximately 15% of lung adenocarcinomas and is associated with a lack of tumour PD-L1 expression, enhanced mTOR activity, CD8 + T cells transformation to exhaustion phenotype and reduction of new infiltrates, neutrophil recruitment [64], blocking of cGAS/STING signalling [57, 65], and resistance to ICB in patients with KRAS-mutant NSCLC (Fig. 1) [57, 65, 66].